KAVI-Institute of Clinical Research (KAVI-ICR), University of Nairobi, recently hosted a high-level delegation from Sanofi for an engaging visit to discuss potential pathways of collaboration and showcase the institute’s robust research capabilities across the continent.

The visit welcomed Dr Monique Adams, Executive Director and Global Head of Diversity and Inclusion in Clinical Trials (DICT) at Sanofi, and Dr Huwaida Bulhan, Africa Region Lead at Sanofi. Their presence marked an important moment in the growing dialogue between leading academic research institutions in Africa and the global biopharmaceutical industry.

Showcasing KAVI-ICR’s Research Portfolio

During the meeting, KAVI-ICR presented an overview of its multidisciplinary research strengths, organised across its core thematic areas:

• Clinical Trials and Experimental Medicine
• Basic and Translational Science
• Observational and Cohort Studies
• Social and Behavioural Research
• Implementation and Health Systems Research
• One Health and Emerging Infections
• Training and Research Capacity Development

Together, these pillars reflect KAVI-ICR’s commitment to producing rigorous, locally relevant, and globally impactful research that addresses the most pressing health needs in Kenya, across Africa, and beyond.

Sanofi’s Vision for Africa

Dr Adams and Dr Bulhan also shared valuable perspectives on Sanofi’s strategic priorities across the African continent. Their remarks highlighted the company’s focus on advancing inclusive clinical research, expanding access to innovative therapies, and building sustainable partnerships that reflect the diversity of patients the biopharmaceutical industry serves. A clear theme emerged from the conversation: that meaningful health innovation in Africa must be co-created with African scientists, institutions, and communities.

A Shared Vision for Collaboration

Speaking on the significance of the engagement, Dr Marianne Mureithi, Director of KAVI-ICR, emphasised the importance of academia and industry working as true partners:

“True progress in global health is never achieved in silos. When academia and industry come together, each bringing its unique strengths to the table, we can translate scientific discovery into solutions that genuinely meet the needs of the populations we serve. Partnerships like this one with Sanofi are essential if we are to deliver equitable, evidence-based, and impactful health interventions for African communities.”

The visit reaffirmed KAVI-ICR’s position as a leading clinical research institution on the continent. It opened the door to deeper conversations on how academic excellence and industry innovation can converge to drive better health outcomes for Africa.

We extend our sincere appreciation to Dr Adams and Dr Bulhan for their visit and for their commitment to advancing equitable, inclusive, and impactful research in Africa.